A polymer composition comprising a polymer and at least one active substance selected from the group consisting of a substance generating an occlusion, in particular a substance generating an internal occlusion or a substance generating an external occlusion; a moisturizing substance; a substance reducing pain or itching; and mixtures of these.

Provided are implants and a glycolytic dependent compound for use in enhancing toxicity of the glycolytic dependent compound towards a cell, tissue and/or organ e.g., a diseased cell, tissue and/or organ, wherein the implant and the glycolytic dependent compound are contacted with the cell, tissue and/or organ in a non-blended form.

Provided are implants and a glycolytic dependent compound for use in enhancing toxicity of the glycolytic dependent compound towards a cell, tissue and/or organ e.g., a diseased cell, tissue and/or organ, wherein the implant and the glycolytic dependent compound are contacted with the cell, tissue and/or organ in a non-blended form.

This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.

This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.

This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.

The present invention relates generally to agents and devices for promoting hemostasis and, more particularly, to bioresorbable hemostatic pads or patches releasably supported on non-resorbable scaffolds for ease of delivery in the field. A sealant and/or hemostat delivery device comprises a resorbable hemostatic pad having a wound facing side and an opposite back side, with a hemostatic and/or wound sealing agent disposed on the wound facing side; a non-resorbable scaffold having an attachment zone on said scaffold; wherein said hemostatic pad is releasably attached with the back side to the attachment zone. The bond between the scaffold and the resorbable hemostatic pad or wound dressing is either (i) severed prior to removal of the scaffold or (ii) is weakened due to the adhesive bonding them together being moisture-deactivated, or (iii) is released by mechanical disentanglement.

The present invention relates generally to agents and devices for promoting hemostasis and, more particularly, to bioresorbable hemostatic pads or patches releasably supported on non-resorbable scaffolds for ease of delivery in the field. A sealant and/or hemostat delivery device comprises a resorbable hemostatic pad having a wound facing side and an opposite back side, with a hemostatic and/or wound sealing agent disposed on the wound facing side; a non-resorbable scaffold having an attachment zone on said scaffold; wherein said hemostatic pad is releasably attached with the back side to the attachment zone. The bond between the scaffold and the resorbable hemostatic pad or wound dressing is either (i) severed prior to removal of the scaffold or (ii) is weakened due to the adhesive bonding them together being moisture-deactivated, or (iii) is released by mechanical disentanglement.

The present invention relates generally to agents and devices for promoting hemostasis and, more particularly, to bioresorbable hemostatic pads or patches releasably supported on non-resorbable scaffolds for ease of delivery in the field. A sealant and/or hemostat delivery device comprises a resorbable hemostatic pad having a wound facing side and an opposite back side, with a hemostatic and/or wound sealing agent disposed on the wound facing side; a non-resorbable scaffold having an attachment zone on said scaffold; wherein said hemostatic pad is releasably attached with the back side to the attachment zone. The bond between the scaffold and the resorbable hemostatic pad or wound dressing is either (i) severed prior to removal of the scaffold or (ii) is weakened due to the adhesive bonding them together being moisture-deactivated, or (iii) is released by mechanical disentanglement.

Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.